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     HLA class II DQA1*01:02-DQB1*06:02 is the strongest genetic risk factor for 
narcolepsy. Since it has been well-established that the level of hypocretin is 
significantly decreased in CSF of narcoleptic patient, I hypothesized that hypocretin 
peptide in hypocretin-producing cells might be presented by 
DQA1*01:02-DQB1*06:02, and induce autoimmune reactions. In the present study, I 
searched for hypocretin-derived peptides that can bind to 
HLA-DQA1*01:02-DQB1*06:02 protein by in vitro binding assay. 
1. I constructed DQA1*01:02-DQB1*06:02, and other narcolepsy-associated 
HLA-DQ molecules. Expression of DQ proteins fused to His-tag or Strep-tag by 
NIH3T3 cells was confirmed by dot-blot analysis for DQA1*01:02-DQB1*06:02. 
2. To determine the reagent with the lowest non-specific binding signal on the NIH3T3 
cell surface, the non-specific binding affinity of various manufacturers’ reagents on 
the NIH3T3 cell surface was examined. The nonspecific binding signals of 
NeutrAvidin DyLight 550 were weakest even at 500 µM.  
3. I examine synthetic peptides designed for prepro-hypocretin as potential 
autoantigens associated with the onset of narcolepsy. The preliminary binding assay 
confirmed the binding of hypocretin signal peptide to narcolepsy-associated proteins. 
Peptides derived from other regions of hypocretin were tested on DQB1*06:02 and 
other allele products. The binding affinities of different risk- and 
protective-HLA-DQ proteins with different hypocretin-derived peptides were 
confirmed. 
4. Insulin B1-15 binds to DQA1*01:02-DQB1*06:02. Insulin B1-15 and insulin B1-20 
(which contains the insulin B1-15 binding motif) as positive controls were analyzed 
in this experiment. However, these assays were unsuccessful in detecting specific 
binding of insulin B1-15 and insulin B1-20, i.e., the positive control peptides, in 
NIH3T3 cells. In the cell-based peptide-binding assay, the assay system exhibited 
high non-specific binding under a variety of conditions.  
5. Eight new hypocretin candidate peptides were evaluated in the plate-based peptide 
binding assay. In particular, the binding intensity of the hypocretin1-13 to 
DQA1*01:03-DQB1*06:03 (resistant haplotype) DQA1*01:03-DQB1*06:03 
(resistant haplotype), and DQA1*01:02-DQB1*06:04 (neutral haplotype) were 
addressed. 
6. The binding of hypocretin-derived peptides to DQ molecules was examined in this 
study. For hypocretin1-13, DQA1*01:02-DQB1*06:02 and 
DQA1*01:03-DQB1*06:03 differ at Phe9β in DQB1*06:02, Tyr9β in DQB1*06:03, 
Tyr30β in DQB1*06:02, and His30β in DQB1*06:03. 9β and 30β are involved in 
accommodating P6 in the binding pocket. The signal intensities of hypocretin1-13 
binding to DQA1*01:03-DQB1*06:03 protein appeared different from 
DQA1*01:02-DQB1*06:02, differences at 9β and 30β may not affect the 
accommodation of P6 valine.  
    The results of the plate-based peptide-binding assay were reproducible for HLA 
DQ protein and hypocretin peptides. Screening a large number of candidate peptides for 
diverse HLA allele products might facilitate the detection of potential epitopes such as 
TRIB2. The results described in this thesis need to be verified by using T cells from 
narcoleptic patients in future studies. The results provide new insights into the epitopes 
and molecular mechanisms underlying narcolepsy and other autoimmune diseases. 
      
 
